ALLOS PHARMA
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The “mGluR theory of fragile X” proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.
ALLOS PHARMA
Industry:
Health Care Life Science Medical Neuroscience Pharmaceutical
Founded:
2019-01-01
Website Url:
http://www.allospharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
Estro technologies s.r.l.
Technologies for neurodevelopmental disorders
Genevant
Delivering solutions through RNA therapeutics.
GreenCom
We make our future green and safe.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Sensus Drug Development Corporation
Sensus Drug Development Corp.
Current Employees Featured
Official Site Inspections
http://www.allospharma.com
- Host name: webcluster7.webpod10-cph3.one.com
- IP address: 77.111.240.70
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
